News for 'Safety Research'

Can avocados help delay diabetes?

Can avocados help delay diabetes?

Rediff.com27 Nov 2019

Avocation B (AvoB), a fat molecule found only in avocados counters incomplete oxidation in skeletal muscle and the pancreas to reduce insulin resistance.

SSLV's second flight scheduled in first quarter of this year: ISRO

SSLV's second flight scheduled in first quarter of this year: ISRO

Rediff.com1 Feb 2023

The SSLV is designed to be affordable and amenable to industry production and aimed to function as a launch-on-demand platform for mini, micro or nano satellites.

Time to book PROFITS in stock markets?

Time to book PROFITS in stock markets?

Rediff.com8 Nov 2021

Even if the bull run may continue, most experts say some profit booking is called for, points out Sanjay Kumar Singh.

Threat of surface Covid transmission increases in winter

Threat of surface Covid transmission increases in winter

Rediff.com18 Dec 2020

Scientists have used virus-like particles to predict how environmental factors affect the survival of the novel coronavirus on surfaces, and found that the COVID-19 virus may remain infectious longer as temperatures drop in winter.

'Most countries won't forgive deaths of children'

'Most countries won't forgive deaths of children'

Rediff.com22 Nov 2022

'The deaths of the children in the Gambia would batter India's reputation as the developing world's pharmacy.'

Final analysis: Covaxin 65.2% effective against Delta variant

Final analysis: Covaxin 65.2% effective against Delta variant

Rediff.com3 Jul 2021

Bharat Biotech's Covaxin has demonstrated 77.8 per cent effectiveness against symptomatic COVID-19 and 65.2 per cent protection against the new Delta variant.

Coronil case: HC asks Ramdev not to mislead people

Coronil case: HC asks Ramdev not to mislead people

Rediff.com17 Aug 2022

The Delhi high court Wednesday told Ramdev that while he was welcome to have his followers, he should not mislead the public by saying more than what is 'official'.

India's entry-level cars lose steam as buyers wait it out in inflation

India's entry-level cars lose steam as buyers wait it out in inflation

Rediff.com31 May 2022

The economy segment of India's car market is unlikely to revive soon term as inflation and prices prompt buyers to defer purchases. The share of entry-level cars in the passenger vehicle market dropped to the lowest in seven years at the end of the Financial Year 2021-22 (FY22). A recovery in the segment will be largely driven by the overall economic growth, improvement in income levels, and easing of semiconductor shortage, say carmakers and analysts.

How Adani Saga Affects Indian Banks

How Adani Saga Affects Indian Banks

Rediff.com27 Feb 2023

While the collapse of a large financial intermediary can wreak havoc on the system because of the interconnectivity, a large business conglomerate too can play spoilsport if the banks have too much exposure to the entity, explains Tamal Bandyopadhyay.

Life is tough for India's gig workers

Life is tough for India's gig workers

Rediff.com13 Feb 2022

The recent protests by employees of Urban Company and the case of a a Zomato delivery executive who died in a road accident point to the severely straitened condition of gig workers during the ongoing Covid-19 pandemic. Budget 2021 had promised several measures to help the cause of gig economy workers, but most of them are yet to see the light of day. Even after a year, the country's gig workers continue to be without any social security cover or a minimum wage guarantee. "In Budget 2021, finance minister Nirmala Sitharaman had announced that the government is looking toward including migrant and gig workers for social security benefits," says Srinivas Kotni, managing partner, Lexport, a consulting firm. Parliament had passed the Code on Wages in 2019 and Code on Industrial Relations, Social Security and Occupational Safety, Health and Working Conditions in 2020.

Covishield accounts for 88% of Covid jabs in India

Covishield accounts for 88% of Covid jabs in India

Rediff.com1 Jan 2022

Serum Institute has the capacity to make 250 million doses of Covishield monthly.

'Everybody's going to get infected'

'Everybody's going to get infected'

Rediff.com27 Dec 2021

'In the likelihood that Omicron is circulating, you have a much greater chance of getting infected now, than you did during the Age of Delta.'

Russian crude will keep flowing into India at least till Dec

Russian crude will keep flowing into India at least till Dec

Rediff.com14 Dec 2022

India will need to travel back in time and seek inspiration from football greats Tulsidas Balaram and Chuni Goswami to deftly dribble around and sidestep the West-imposed price cap on exports of Russian seaborne crude oil. India depends on imported oil to meet 86 per cent of its needs, of which nearly a quarter now comes from Russia. The copious flows are roughly 10 per cent cheaper than competing suppliers helping India save billions of dollars in fuel costs.

New technology adds zing to Indian Railways

New technology adds zing to Indian Railways

Rediff.com4 Mar 2020

Globally, London's Tube and French railway networks are already using this technology in their corrosion-prone areas.

Gennova's mRNA Covid vaccine gets nod for Phase 2-3 trials

Gennova's mRNA Covid vaccine gets nod for Phase 2-3 trials

Rediff.com25 Aug 2021

If things go according to plan, the vaccine would be available in the market by the end of this year.

How govt will judge the performance of PSUs

How govt will judge the performance of PSUs

Rediff.com11 May 2022

The number of times public sector undertakings (PSUs) have held conference calls with investors, their capital management, and debt financing are among the parameters that the Centre will use to judge their performance for the first time, a senior official in the know said. The government will evaluate PSUs for FY22 based on new parameters that were finalised by the Department of Public Enterprises (DPE) in consultation with the Department of Investment and Public Asset Management (DIPAM) last year, the official said. The government had included more conditions in the memorandum of understandings (MoUs) - used to set annual targets - that public sector enterprises sign with the DPE every year. These included a consistent dividend policy, which seeks to transfer dividends by PSUs every quarter; and market capitalisation or share price improvement over the sectoral index on an annual average basis for listed companies.

Cyclone Yaas: DRDO to protect missile testing facilities

Cyclone Yaas: DRDO to protect missile testing facilities

Rediff.com25 May 2021

The Integrated Test Range of Defence Research and Development Organisation (DRDO) has taken various measures to protect its facilities at Chandipur and Abdul Kalam Island in Odisha, which are likely to be affected by cyclone 'Yaas', an official said.

Why Dr Reddy's had to shut all its units

Why Dr Reddy's had to shut all its units

Rediff.com25 Oct 2020

Security breach came days after the firm got approval to conduct trials for Covid-19 vaccine candidate Sputnik V.

Sensex slides by 135 points as markets fall for 6th straight day

Sensex slides by 135 points as markets fall for 6th straight day

Rediff.com17 Jun 2022

Market benchmarks gave up intra-day gains to close in the red for the sixth session on the trot on Friday, capping a bruising week which saw a massive dash for safety amid rate hikes by global central banks and fears of slowing growth.

Amid row, ICMR defends COVID-19 vaccine deadline

Amid row, ICMR defends COVID-19 vaccine deadline

Rediff.com4 Jul 2020

ICMR says it is following all globally accepted norms to fast-track vaccine and wants to 'cut red tape'.

'If junk stocks are rising, one has to be careful'

'If junk stocks are rising, one has to be careful'

Rediff.com16 Dec 2020

'Investors should put their money in stocks where the margin of safety is high.'

When will Covid end? Here's what experts say

When will Covid end? Here's what experts say

Rediff.com15 Feb 2022

'Unless we see four weeks of low and stable numbers with only minor fluctuations, we cannot call the valley as endemic just as yet'

10 things to know about COVID-19 vaccines

10 things to know about COVID-19 vaccines

Rediff.com16 Jan 2021

As India holds its breath for the Covid vaccination to be begin, Sudhir Bisht provides a quick checklist of what you must know about the vaccines that will be administered to citizens.

Bharat Biotech asked to submit phase 2 data of its Covid vaccine

Bharat Biotech asked to submit phase 2 data of its Covid vaccine

Rediff.com10 Oct 2020

The vaccine candidate -- 'Covaxin' -- is being indigenously developed by the Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR).

Despite Jammu attack India set to relax drone policy

Despite Jammu attack India set to relax drone policy

Rediff.com14 Jul 2021

While there were concerns about the security aspect of drones, top government officials were of the view that restricting the drone industry would stifle a sunrise sector which holds significant promise for future, reports Arindam Majumder.

Lancet Study finds Russian vaccine safe, effective

Lancet Study finds Russian vaccine safe, effective

Rediff.com4 Sep 2020

Results from early-phase non-randomised vaccine trials in a total of 76 people show that two formulations of the vaccine have a good safety profile detected over 42 days, and induce antibody responses in all participants within 21 days.

World could enter worst part of pandemic: Bill Gates

World could enter worst part of pandemic: Bill Gates

Rediff.com22 Dec 2021

Gates, 66, on Tuesday, said that "I know it's frustrating to go into another holiday season with COVID looming over us. But it won't be like this forever. Someday the pandemic will end, and the better we look after each other, the sooner that time will come."

Covaxin maker to pay compensation in case of side effects

Covaxin maker to pay compensation in case of side effects

Rediff.com16 Jan 2021

"The compensation for serious adverse event will be paid by sponsor (BBIL) in case if the SAE is proven to be causally related to the vaccine," the consent form said.

WHO to decide next week on approval to Covaxin

WHO to decide next week on approval to Covaxin

Rediff.com5 Oct 2021

'WHO & an independent group of experts are scheduled to meet next week to carry out the risk/benefit assessment and come to a final decision whether to grant Emergency Use Listing to Covaxin,' the global health body tweeted.

Russia seeks Indian help in manufacturing COVID-19 vaccine

Russia seeks Indian help in manufacturing COVID-19 vaccine

Rediff.com26 Aug 2020

According to government sources, the matter was discussed by the national expert group on vaccine administration for COVID-19 in its last meeting held on August 22.

India launches short range surface-to-air missile twice

India launches short range surface-to-air missile twice

Rediff.com22 Feb 2021

On both the occasions, the missiles intercepted the simulated targets with pinpoint accuracy. The missiles were tested for minimum and maximum range.

Covaxin's 50 pc efficacy adequate for Covid, say experts

Covaxin's 50 pc efficacy adequate for Covid, say experts

Rediff.com26 Nov 2021

The decline in the effectiveness of Covaxin, India's indigenous COVID-19 vaccine, from 77.8 per cent to 50 per cent during a Delta-driven case surge in April and May this year is neither bad nor surprising, say scientists.

COVID-19 vaccine unlikely before Fall of 2021: Experts

COVID-19 vaccine unlikely before Fall of 2021: Experts

Rediff.com2 Oct 2020

Researchers at McGill University in Canada carried out a survey of 28 experts working in vaccinology in late June 2020. The majority of those surveyed were mostly Canadian or American academics with an average of 25 years of experience working in the field.

J&J seeks permission for trial of 1-shot Covid vaccine in India

J&J seeks permission for trial of 1-shot Covid vaccine in India

Rediff.com20 Apr 2021

The US Food and Drug Administration had in February approved Johnson & Johnson's COVID-19 vaccine that works with just one dose for emergency use.

Govt may defer LIC IPO to next fiscal amid Ukraine crisis

Govt may defer LIC IPO to next fiscal amid Ukraine crisis

Rediff.com6 Mar 2022

The government is expected to defer the mega initial public offering (IPO) of LIC to the next financial year as the ongoing Russia-Ukraine war has dampened fund managers' interest in the public issue, market experts said on Sunday. The government was looking to sell 5 per cent stake in Life Insurance Corporation (LIC) this month, which could have fetched over Rs 60,000 crore to the exchequer. The IPO would have helped meet the curtailed divestment target of Rs 78,000 crore this fiscal.

Furore over 'Rashtrapatni' remark reignites gender debate

Furore over 'Rashtrapatni' remark reignites gender debate

Rediff.com28 Jul 2022

In the last 75 years, there have been multiple calls for a gender-neutral term for the head of the State and debates over it.

Oxford COVID-19 vaccine hopes rise with strong trial results

Oxford COVID-19 vaccine hopes rise with strong trial results

Rediff.com16 Jul 2020

Blood samples taken from a group of UK volunteers given a dose of the vaccine showed that it stimulated the body to produce both antibodies and 'killer T-cells', a senior source from the trial was quoted by The Daily Telegraph as saying.

Covaxin: No serious adverse events in phase 1 trials

Covaxin: No serious adverse events in phase 1 trials

Rediff.com16 Dec 2020

The vaccine induced robust binding and neutralising antibody responses which were comparable to those observed in the convalescent serum collected from patients who had recovered from COVID-19, according to the findings which have appeared on medRxiv, a preprint server.

F1 boss breaks silence on Hamilton's jewellery battle

F1 boss breaks silence on Hamilton's jewellery battle

Rediff.com16 May 2022

Lewis Hamilton and the FIA were in a standoff at this month's Miami Grand Prix over piercings

Sensex drops 273 pts on sell-off in pharma, bank stocks

Sensex drops 273 pts on sell-off in pharma, bank stocks

Rediff.com27 Jul 2021

Equity benchmark Sensex tumbled over 273 points on Tuesday, tracking losses in index majors Reliance Industries, Dr Reddy's and Axis Bank amid a massive selloff in Chinese markets. Despite opening on a positive note, the 30-share BSE index turned red to end 273.51 points or 0.52 per cent lower at 52,578.76, while the broader NSE Nifty fell 78 points or 0.49 per cent to 15,746.45. Dr Reddy's was the top loser in the Sensex pack, plunging over 10 per cent, after the company reported s 36 per cent decline in consolidated net profit at Rs 380.4 crore for the quarter ended June 30, 2021, on account of higher expenses.